Is highly purified cannabidiol a treatment opportunity for drug‐resistant epilepsy in subjects with typical Rett syndrome and <scp>CDKL5</scp> deficiency disorder?
Aglaia Vignoli(University of Milan), Nicola Specchio(Bambino Gesù Children's Hospital), Giulia Prato(Istituto Giannina Gaslini), Maria Paola Canevini(University of Milan), Jacopo Favaro(University of Padua), Alberto Danieli(IRCCS Eugenio Medea), Miriam Nella Savini(European Hospital), Emilia Ricci(University of Milan), Irene Bagnasco(Ospedale Martini), Ilaria Viganò(Ospedale Valduce), Davide Paolo Bernasconi(University of Milano-Bicocca), Lino Nobili(Centro Studi GISED), Alessandro Orsini(University of Pisa), Francesca Felicia Operto(Magna Graecia University), Massimiliano Celario(University of Pavia), Valentina De Giorgis(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Paolo Bonanni(IRCCS Eugenio Medea), Stefano Sartori(University of Padua), Sara Matricardi(Ospedali Riuniti di Ancona), Luca Manfredini(Istituto Giannina Gaslini), Nicola Pietrafusa(Bambino Gesù Children's Hospital), Giulia Balletto(Istituto Giannina Gaslini), Enrico Alfei(Ospedale dei Bambini Vittore Buzzi)
Cited by 5
Related Papers
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry
|The Lancet Neurology|2018|537
The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies
|Frontiers in Neurology|2021|260
NREM sleep parasomnias as disorders of sleep-state dissociation
|Nature Reviews Neurology|2018|200